Skip to main content

This job has expired

You will need to login before you can apply for a job.

Director, Competitive Intelligence & Analytics

Precision BioSciences, Inc.
Durham, NC
Start date
Apr 21, 2024

Job Details

Precision Biosciences, Inc. seeks Director, Competitive Intelligence & Analytics in Durham, NC. Duties: Develop deep market and business insights through competitive intelligence efforts, data analytics, and market observations for key programs across our pipeline, including future technologies. Shape corporate and program strategies as well as support critical business development efforts by leading, developing, and owning valuation models. Provide critical competitive and business intelligence inputs and recommendations to help drive Company’s development objectives in the area of in-vivo gene editing, including the associated delivery platforms (e.g., AAV/LNP). Assist with business development efforts, in particular deal model creation, valuation, and analysis to support potential transactions. Innovate and embed ways of working to gather CI and develop key reports and action-orientated insights to build a best-in-class CI capability for Precision BioSciences. Lead the organization’s intelligence capabilities by conceptualizing and driving innovative approaches to competitive insights / research that impact strategic business decision making. Plan and facilitate key Competitor Workshops (War Games, Gap Analysis, Scenario Planning) to prepare teams for future potential competitor threats. Directly interface with broad set of stakeholders including Executive Leadership, R&D organization, and Finance/Investor Relations to serve as the subject matter expert for competitive intelligence and secondary analytics. Act as an objective, critical and strategic advisor to Precision based on deep expertise in current and future competitive drivers in the marketplace. Develop holistic and predictive competitor landscape assessments based on a thorough understanding and analysis of internal and external business issues; employ robust CI sources and methodologies; ensure integration of intelligence and CI deliverables into brand planning, forecasting, clinical trial planning, and strategic decision making. Lead competitive intelligence planning and execution for key congresses and investor meetings with input from Precision teams and/or third-party agencies; drive Precision team preparedness, develop key intelligence questions and areas of focus, align onsite activities, and consolidate key insights and disseminate post-congress. Ensure all CI research activities are conducted within appropriate code of conduct, compliance, and ethical business practices; role-model to build and teach capability across Precision Biosciences.

Requirements: Master’s degree in biological sciences or related field of study plus 5 years of experience in competitive intelligence, business development marketing, market intelligence, analytics, or related role within the biopharmaceutical/pharmaceutical industry.

Must have 5 years of competitive intelligence experience within at least one or more of the following areas: oncology, gene or cell therapy, delivery (AAV/LNP) across the product life cycle, or early-stage assets.

Must have experience with:

  • Planning and facilitating simulation workshops (war wages, gap analysis, scenario planning) to prepare for potential competitor threats.
  • Forecasting development with market that integrates epidemiology insights.
  • Leveraging forecast models.
  • Using online data sources and scientific databases.
  • Presenting CI insights to senior executives.
  • Budget and vendor management.
  • Able to telecommute from any location within the U.S. 20% national and international travel required to attend congresses and investor meetings as part of regular job duties.


    Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing and ex vivo allogeneic CAR T therapies with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly sophisticated edits for gene insertion and/or gene repair. Precision’s in vivo gene editing pipeline consists of wholly-owned preclinical candidates for primary hyperoxaluria type 1 (PBGENE-PH1), familial hypercholesteremia (PBGENE-PCSK9) and chronic hepatitis B (PBGENE-HBV). It has also partnered with Lilly to develop candidates for Duchenne muscular dystrophy and two other programs targeting the liver and CNS. Precision’s allogeneic CAR T pipeline consists of multiple investigational candidates in early-stage clinical trials, including its first and second generation CD19 targeting candidates PBCAR0191 and PBCAR19B for relapsed and/or refractory (R/R) non-Hodgkin and B-cell lymphoma patients. Precision has also prioritized development of PBCAR269A, its BCMA targeted candidate in combination with a gamma secretase inhibitor for R/R patients with multiple myeloma. Precision BioSciences and its in-house manufacturing facility for AAV, mRNA, and CAR T cells is based in Durham, North Carolina. For more information about Precision BioSciences please visit

    Stock Symbol: DTIL

    Stock Exchange: NASDAQ

    Company info
    302 East Pettigrew Street
    North Carolina

    Get job alerts

    Create a job alert and receive personalized job recommendations straight to your inbox.

    Create alert